Journal article
Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.
Abstract
4539
Background: Performance status (PS), hemoglobin (Hb), liver metastasis (LM), and time from prior chemotherapy (TFPC) are significant prognostic factors in second-line therapy for advanced UC. Setting of prior chemotherapy, i.e., metastatic or perioperative, has not appeared significant. However, the impact of prior chemosensitivity is unclear, which may confound trial interpretation. Hence, we examined the prognostic …
Authors
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Salhi Y; Niegisch G; Albers P; Di Lorenzo G; Galsky MD
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. 4539–4539
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.4539
ISSN
0732-183X